The company charged with reinstating the heirs of Holocaust victims who had assets in Israel will provide a large chunk of its funding this year to the Cameri Theater.
The Company for Location and Restitution said that it will distribute a total of NIS 5 million this year for Holocaust commemoration and education activities. Of this sum, the Cameri will receive NIS 1.4 million to enable tens of thousands of soldiers and students to see the play "Ghetto."
The company, which was founded in 2007, is obligated by law to allocate funds from unclaimed assets to help Holocaust survivors in need as well as to fund Holocaust memorial and education projects.
The company will also provide the organization Beit Edut with NIS 882,000 to fund a trip for school children and a meeting with survivors. The Hebrew University in Jerusalem will receive NIS 658,000 for its Multimedia Center, and Yad Vashem, the Holocaust Martyrs and Heroes Remembrance Authority, will receive NIS 500,000. The Hashomer Hatzair youth movement, Beit Berl and the Center for Educational Technologies will also receive funds.
The allocation to the Cameri Theater is meant to finance about 50 performances for 40,000 soldiers and students.
The play "Ghetto," written by Joshua Sobol and directed by Omri Nitzan, describes the final days of the theater that operated in the Vilna Ghetto during the Nazi occupation of Lithuania. Actors Itay Tiran, Natan Datner, Anya Bukstein, Hani Furstenberg, Gadi Yagil and Rami Baruch perform in the play.
Anonymous sources familiar with the issue criticized the company's decision to give the largest sum to the theater. They said the company should have invested the money in documentation or more profound studies about the Holocaust.
Company sources said decisions about the allocation of funding were made by an independent public committee headed by Professor Mordechai Shani. They said funding of different projects will be conditioned on an external company's supervision of their implementation.
Want to enjoy 'Zen' reading - with no ads and just the article? Subscribe todaySubscribe now